About
Technology
Issues
FAQ
Search
filter by year
2023 (469)
2022 (809)
2021 (859)
2020 (1,211)
2010-2019 (4,472)
2000-2009 (1,253)
1990-1999 (369)
1980-1989 (197)
1970-1979 (113)
1960-1969 (68)
1950-1959 (49)
1900-1950 (61)
Similar Keywords
laroche (170)
roche (9,860)
1-20 of (10,030 documents found)
2011
1.6K
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
New England Journal of Medicine
(
13.9
★★★
), 365, 2484-2496.
Cite
Citations
Matthew Li (80, 6.9K)
2015
442
Facts and fictions about polymorphism
Chemical Society Reviews
(
18.7
★★★
), 44, 8619-8635.
Cite
Citations
Matthew Li (80, 6.9K)
2011
2.4K
Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons
Genome Research
(
2.4
★★★
), 21, 494-504.
Cite
Citations
Matthew Li (80, 6.9K)
2012
1.1K
Performance comparison of benchtop high-throughput sequencing platforms
Nature Biotechnology
(
9.4
★★★
), 30, 434-439.
Cite
Citations
Matthew Li (80, 6.9K)
2006
543
Antiviral agents active against influenza A viruses
Nature Reviews Drug Discovery
(
21.5
★★★
), 5, 1015-1025.
Cite
Citations
Matthew Li (80, 6.9K)
2019
544
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
Lancet Oncology, The
(
5.1
★★★
), 20, 663-673.
Cite
Citations
Matthew Li (80, 6.9K)
2017
261
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
New England Journal of Medicine
(
13.9
★★★
), 377, 1250-1260.
Cite
Citations
Matthew Li (80, 6.9K)
2016
624
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Lancet Oncology, The
(
5.1
★★★
), 17, 738-746.
Cite
Citations
Matthew Li (80, 6.9K)
2012
418
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
(
13.9
★★★
), 366, 299-309.
Cite
Citations
Matthew Li (80, 6.9K)
2019
373
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Lancet, The
(
6.3
★★★
), 393, 1453-1464.
Cite
Citations
Matthew Li (80, 6.9K)
2014
667
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Lancet Oncology, The
(
5.1
★★★
), 15, 747-756.
Cite
Citations
Matthew Li (80, 6.9K)
2015
548
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncology, The
(
5.1
★★★
), 16, 928-936.
Cite
Citations
Matthew Li (80, 6.9K)
2003
889
An extended upper atmosphere around the extrasolar planet HD209458b
Nature
(
13.7
★★★
), 422, 143-146.
Cite
Citations
Matthew Li (80, 6.9K)
2005
638
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
New England Journal of Medicine
(
13.9
★★★
), 353, 2111-2120.
Cite
Citations
Matthew Li (80, 6.9K)
2017
351
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Lancet, The
(
6.3
★★★
), 389, 2031-2040.
Cite
Citations
Matthew Li (80, 6.9K)
2012
872
Comparison of Next-Generation Sequencing Systems
Journal of Biomedicine and Biotechnology
(
3.0
★★★
), 2012, 1-11.
Cite
Citations
Matthew Li (80, 6.9K)
2016
350
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Lancet, The
(
6.3
★★★
), 387, 1921-1927.
Cite
Citations
Matthew Li (80, 6.9K)
2011
562
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Lancet, The
(
6.3
★★★
), 378, 1779-1787.
Cite
Citations
Matthew Li (80, 6.9K)
2020
245
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Lancet Infectious Diseases, The
(
4.6
★★★
), 20, 1390-1400.
Cite
Citations
Matthew Li (80, 6.9K)
2015
365
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lancet, The
(
6.3
★★★
), 385, 1843-1852.
Cite
Citations
Matthew Li (80, 6.9K)
1
2
3
site/software ©
exaly
; All materials licenced under
CC by-SA
.